RT Journal Article
SR Electronic
T1 What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.26.20180950
DO 10.1101/2020.08.26.20180950
A1 L. Sigfrid
A1 M. Cevik
A1 E. Jesudason
A1 W.S Lim
A1 J. Rello
A1 J. H. Amuasi
A1 F. Bozza
A1 C. Palmieri
A1 D. Munblit
A1 J.C. Holter
A1 A.B. Kildal
A1 C.D. Russell
A1 A. Ho
A1 L. Turtle
A1 T.M. Drake
A1 A. Beltrame
A1 K. Hann
A1 I.R. Bangura
A1 R. Fowler
A1 S. Lakoh
A1 C. Berry
A1 D.J. Lowe
A1 J. McPeake
A1 M. Hashmi
A1 A.M. Dyrhol-Riise
A1 C. Donohue
A1 D.R. Plotkin
A1 H. Hardwick
A1 N. Elkheir
A1 N. Lone
A1 A.B. Docherty
A1 E.M. Harrison
A1 K.J. Baille
A1 G. Carson
A1 M.G. Semple
A1 J.T. Scott
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.26.20180950.abstract
AB Introduction Very little is known about possible clinical sequelae that may persist after resolution of the acute Coronavirus Disease 2019 (COVID-19). A recent longitudinal cohort from Italy including 143 patients recovered after hospitalisation with COVID-19 reported that 87% had at least one ongoing symptom at 60 day follow-up. Early indications suggest that patients with COVID-19 may need even more psychological support than typical ICU patients. The assessment of risk factors for longer term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of illness.Methods and analysis This is an international open-access prospective, observational multi-site study. It will enrol patients following a diagnosis of COVID-19. Tier 1 is developed for following up patients day 28 post-discharge, additionally at 3 to 6 months intervals. This module can be used to identify sub-sets of patients experiencing specific symptomatology or syndromes for further follow up. A Tier 2 module will be developed for in-clinic, in-depth follow up. The primary aim is to characterise physical consequences in patients post-COVID-19. Secondary aim includes estimating the frequency of and risk factors for post-COVID-19 medical sequalae, psychosocial consequences and post-COVID-19 mortality. A subset of patients will have sampling to characterize longer term antibody, innate and cell-mediated immune responses to SARS-CoV-2.Ethics and dissemination This collaborative, open-access study aims to characterize the frequency of and risk factors for long-term consequences and characterise the immune response over time in patients following a diagnosis of COVID-19 and facilitate standardized and longitudinal data collection globally. The outcomes of this study will inform strategies to prevent long term consequences; inform clinical management, direct rehabilitation, and inform public health management to reduce overall morbidity and improve outcomes of COVID-19.Strengths and limitations of this studyAs an international prospective, observational study we provide open-access standardised tools that can be adapted by any site interested in following up patients with COVID-19, for independent or combined analysis, to forward knowledge into short and long term consequences of COVID-19.This study aims to inform strategies to prevent longer term sequalae; inform clinical management, rehabilitation, and public health management strategies to reduce morbidity and improve outcomes.The protocol will be used for a sub-set of patients, already included in the existing cohort of more than 85,973 individuals hospitalized with confirmed COVID-19 infection across 42 countries (as of 20 July 2020), using the ISARIC/WHO standardized Core- or RAPID Case Report Forms (CRFs).The data will be linked with data on pre-existing comorbidities, presentation, clinical care and treatments documented in the existing cohort already documented using the ISARIC/WHO standardized Core- or RAPID CRFs.The data collection tool is developed to facilitate wide dissemination and uptake, by enabling patient self-assessment, however, follow up of patients requires consent and resources, which might limit the uptake and bias the data towards countries /sites with capacity to follow up patients over time.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialosf.io/c5rw3/Clinical Protocols https://isaric.tghn.org/CCP/isaric-global-covid-19-long-term-follow-study/ Funding StatementThis work was supported by the Department for International Development and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135]. CP would like to acknowledge the support of the Liverpool Experimental Cancer Medicine Centre (Grant Reference: C18616/A25153) and The Clatterbridge Cancer Centre Charity. CB acknowledges the support from British Heart Foundation RE/18/6134217.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a multi-site global prospective COVID-19 observational follow up study protocol, developed by the ISARIC COVID-19 Global Follow up working group. Each site that sets up the study will seek local ethical approvals as appropriate.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesISARIC stands by the principles of data sharing in public health emergencies. ISARIC supported studies will share quality data in a timely, valid, and governed manner to inform public health policy and benefit patient care. The ISARIC-hosted data platform enables rapid and harmonised operationalisation of data collection to a secure database. Ownership and control of the data entered are retained by those who enter the data. Sites can contribute data to combined analysis upon permission. Technical appendix, statistical code and datasets are available from https://isaric.tghn.org/ or by contacting: ncov{at}isaric.org. https://isaric.tghn.org/CCP/isaric-global-covid-19-long-term-follow-study/